<p class="MsoNormal">The spin-off of GSK’s consumer healthcare unit<span style="color:#202124"><span style="background-color:#ffffff">—</span></span>Haleon<span style="color:#202124"><span style="background-color:#ffffff">—</span></span>was worth around $36.5 billion (£30.5 billion) when it started trading in London Monday.</p>
